-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 5, 2023, Cytomx announced a collaboration agreement with Moderna to jointly develop a new proantibody drug
for mRNA expression.
Under the agreement, Moderna pays an upfront payment of $35 million (including $5 million in research and development expenses), a $1.
2 billion milestone amount, and a percentage share of
sales.
Affected by this news, Cytomx shares jumped 60%
after hours.
Cytomx is a pioneer in proantibody technology, and its Probody technology is used in a wide range of drug formats, including monoclonal antibodies, dual antibodies, ADCs, and cytokines
.
summary
summaryCytomx's proantibodies have reached cooperation with many large companies, including BMS, Astellas, Moderna, etc.
, but the clinical progress of its own R&D pipeline is not smooth, and the preantibody technology has never completed a major clinical breakthrough
.
In any case, it is hoped that the ongoing clinical exploration will eventually make progress
.
